Suppr超能文献

调控 NRF2 在疾病中的作用:时机至关重要。

Modulating NRF2 in Disease: Timing Is Everything.

机构信息

Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona 85721, USA; email:

Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA.

出版信息

Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:555-575. doi: 10.1146/annurev-pharmtox-010818-021856. Epub 2018 Sep 26.

Abstract

The transcription factor nuclear factor erythroid 2 (NF-E2)-related factor 2 (NRF2) is a central regulator of redox, metabolic, and protein homeostasis that intersects with many other signaling cascades. Although the understanding of the complex nature of NRF2 signaling continues to grow, there is only one therapeutic targeting NRF2 for clinical use, dimethyl fumarate, used for the treatment of multiple sclerosis. The discovery of new therapies is confounded by the fact that NRF2 levels vary significantly depending on physiological and pathological context. Thus, properly timed and targeted manipulation of the NRF2 pathway is critical in creating effective therapeutic regimens. In this review, we summarize the regulation and downstream targets of NRF2. Furthermore, we discuss the role of NRF2 in cancer, neurodegeneration, and diabetes as well as cardiovascular, kidney, and liver disease, with a special emphasis on NRF2-based therapeutics, including those that have made it into clinical trials.

摘要

转录因子红系 2 相关因子 2(NRF2)是氧化还原、代谢和蛋白质稳态的中央调节剂,与许多其他信号级联相交。尽管对 NRF2 信号的复杂性质的理解不断加深,但只有一种针对 NRF2 的治疗方法,即二甲基富马酸,用于治疗多发性硬化症。新疗法的发现受到 NRF2 水平因生理和病理情况而异的事实所困扰。因此,正确的时机和靶向 NRF2 途径的操作对于制定有效的治疗方案至关重要。在这篇综述中,我们总结了 NRF2 的调节和下游靶标。此外,我们还讨论了 NRF2 在癌症、神经退行性疾病和糖尿病以及心血管、肾脏和肝脏疾病中的作用,特别强调了基于 NRF2 的治疗方法,包括已进入临床试验的治疗方法。

相似文献

1
Modulating NRF2 in Disease: Timing Is Everything.
Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:555-575. doi: 10.1146/annurev-pharmtox-010818-021856. Epub 2018 Sep 26.
2
The role of the Nrf2/Keap1 pathway in obesity and metabolic syndrome.
Rev Endocr Metab Disord. 2015 Mar;16(1):35-45. doi: 10.1007/s11154-014-9305-9.
3
Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression.
Am J Nephrol. 2017;45(6):473-483. doi: 10.1159/000475890. Epub 2017 May 13.
5
Counteracting role of nuclear factor erythroid 2-related factor 2 pathway in Alzheimer's disease.
Biomed Pharmacother. 2020 Sep;129:110373. doi: 10.1016/j.biopha.2020.110373. Epub 2020 Jun 27.
7
Regulation of the Nrf2 antioxidant pathway by microRNAs: New players in micromanaging redox homeostasis.
Free Radic Biol Med. 2013 Sep;64:4-11. doi: 10.1016/j.freeradbiomed.2013.07.025. Epub 2013 Jul 21.
8
Inhibition of the NRF2/KEAP1 Axis: A Promising Therapeutic Strategy to Alter Redox Balance of Cancer Cells.
Antioxid Redox Signal. 2021 Jun 20;34(18):1428-1483. doi: 10.1089/ars.2020.8146. Epub 2021 Feb 19.
9
The Keap1/Nrf2 pathway in health and disease: from the bench to the clinic.
Biochem Soc Trans. 2015 Aug;43(4):687-9. doi: 10.1042/BST20150069. Epub 2015 Aug 3.
10
The intricacies of NRF2 regulation in cancer.
Semin Cancer Biol. 2021 Nov;76:110-119. doi: 10.1016/j.semcancer.2021.05.016. Epub 2021 May 18.

引用本文的文献

1
Exploring the role of ferroptosis in esophageal cancer: mechanisms and therapeutic implications.
Cell Death Discov. 2025 Aug 25;11(1):405. doi: 10.1038/s41420-025-02696-2.
6
Protective Effect of Hordenine on Concanavalin A-Induced Hepatic Injury.
J Inflamm Res. 2025 Jul 23;18:9823-9835. doi: 10.2147/JIR.S507792. eCollection 2025.
8
Ferroptosis in ocular diseases: mechanisms, crosstalk with other cell death pathways, and therapeutic prospects.
Front Med (Lausanne). 2025 Jul 8;12:1608975. doi: 10.3389/fmed.2025.1608975. eCollection 2025.

本文引用的文献

2
NRF2-targeted therapeutics: New targets and modes of NRF2 regulation.
Curr Opin Toxicol. 2016 Dec;1:62-70. doi: 10.1016/j.cotox.2016.10.005. Epub 2016 Oct 12.
3
Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression.
Am J Nephrol. 2017;45(6):473-483. doi: 10.1159/000475890. Epub 2017 May 13.
5
6
Brusatol overcomes chemoresistance through inhibition of protein translation.
Mol Carcinog. 2017 May;56(5):1493-1500. doi: 10.1002/mc.22609. Epub 2017 Feb 8.
8
Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers.
Cell Rep. 2016 Sep 6;16(10):2605-2617. doi: 10.1016/j.celrep.2016.08.010. Epub 2016 Aug 25.
9
Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors.
ACS Chem Biol. 2016 Nov 18;11(11):3214-3225. doi: 10.1021/acschembio.6b00651. Epub 2016 Oct 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验